This retrospective analysis compared auto-HSCT and allo-HSCT with tandem auto-HSCT and auto-allo-HSCT to determine which strategy provided better PFS and OS for patients with multiple myeloma.
This “Clinical Picture” describes a case of extramedullary multiple myeloma manifesting as a rapidly growing intraoral lesion.
Only about one-third of patients required hospital admission.
The addition of plerixafor to treatment following transplantation may not enhance lymphocyte recovery in patients with multiple myeloma.
The TEAMM trial sought to assess time to first febrile episode or death from all causes in patients with newly diagnosed myeloma who received antibiotic prophylaxis vs those who did not.
[OncoTargets and Therapy] In this review, researchers describe the pathophysiology of myeloma bone disease and discuss the significance of preventing skeletal-related events in patients with MM.
Researchers explored a possible link between TNF-α and peripheral neuropathy in patients with MM treated with bortezomib.
Uncertainty is defined in this study as “the inability to give sense or meaning to the processes or situations that have to do with medical conditions.”
Patients receiving the 3-drug treatment experienced increasing rates of complete response and measurable residual disease from induction through consolidation.
Progression-free survival significantly longer with lenalidomide compared with observation.
